BC
AUPH icon

Brookfield Corp’s Aurinia Pharmaceuticals AUPH Stock Holding History

Brookfield Corp’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,633
Closed -$1.46M – 147
2023
Q2 		$1.46M Buy
+150,633
New +$1.56M 0.01% 437
2022
Q1 		– Sell
-240,000
Closed -$3.71M – 621
2021
Q4 		$5.49M Buy
240,000
+191,482
+395% +$4.54M 0.02% 203
2021
Q3 		$1.07M Buy
48,518
+1,211
+3% +$19.2K ﹤0.01% 411
2021
Q2 		$613K Buy
+47,307
New +$603K ﹤0.01% 498

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brookfield Corp's AUPH Position: Q3 2023 in Review

Brookfield Corp sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 150,633 shares — an estimated $1.46M sold.

Brookfield Corp first reported a position in AUPH in Q2 2021 and held it in 4 quarters. The position peaked at $5.49M in Q4 2021. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Brookfield Corp reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 150,633 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $1.46M.
  • Brookfield Corp first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Brookfield Corp's Aurinia Pharmaceuticals position peaked at $5.49M in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.